Stockreport

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Marinus Pharmaceuticals, Inc.  (MRNS) 
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.marinuspharma.com/investor-relations
PDF ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023Narrowing full year 2024 ZTALMY net product revenue guidance to [Read more]